Kornimate/medical-research-clean huggingface dataset:
clinical efficacy of hybenix vs chlosite gels in peri-implantitis

Conditions: Peri-Implantitis

Summary: the present study is a randomized clinical trial (rct). patients responding to the inclusion criteria will be included. the following peri-implant indexes will be collected: bleeding on probing, gingival bleeding index, marginal mucosal conditions (swelling and erythema), suppuration, mucosal margin migration, ppd probing pocket depth, plaque index, bleeding score, radiographic bone loss. after the peri-implant evaluation, patients will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with peek inserts, manual instrumentation with teflon curettes and air polishing with glycine powder. after that, the sample will be randomly divided into 2 groups based on thein-office assigned treatment: * chlosite® gel application in the peri-implant sulcus * hybenix® gel application for 30 s followed by rinsing of the peri-implant sulcus. the study will last 9 months. patients will be visited at: t0, after 1 month from t0 (t1), after 3 months (t2), after 6 months (t3) and after 9 months (t4). in each time frame, indexes collection and nonsurgical debridement will be performed.

the present study is designed as a randomized clinical trial (rct) to evaluate the clinical efficacy of two adjuvant gels in the treatment of perimplantitis. patients responding to the inclusion criteria will be included in the study. the following peri-implant indexes will be collected: * bop (bleeding on probing) * gbi (gingival bleeding index) * marginal mucosal conditions (swelling and erythema) * suppuration * mucosal margin migration * ppd (probing pocket depth) * pi (plaque index) * bs (bleeding score) * radiographic bone loss after the peri-implant evaluation, patients will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with peek inserts, manual instrumentation with teflon curettes and air polishing with glycine powder. after that, the sample will be randomly divided into 2 groups based on thein-office assigned treatment: * chlosite® gel application in the peri-implant sulcus * hybenix® gel application for 30 s followed by rinsing of the peri-implant sulcus. the study will last 9 months. patients will be visited at: t0, after 1 month from t0 (t1), after 3 months (t2), after 6 months (t3) and after 9 months (t4). in each time frame, indexes collection and nonsurgical debridement will be performed.

Eligibility criteria:
inclusion criteria: - presence of at least one peri-implant site with perimplantitis diagnosed according to the latest classification of periodontal and peri-implant diseases and conditions \[berglundh et al., 2018\] exclusion criteria: * patient with cardiac pacemaker * patients suffering from psychological, neurological or psychiatric disorders * patients suffering from systemic, metabolic or autoimmune diseases * pregnant women

Keywords: chlorhexidine hybenix gel domiciliary treatments
clinical trial with msc for graft versus host disease treatment

Conditions: Acute Graft Versus Host Disease

Summary: sequential administration of mscs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.

multicenter, open, non -controlled clinical trial. it is a phase i-ii trial to assess the safety and efficacy of sequential infusion of allogeneic mscs from adipose tissue, expanded "in vitro" platelet lysate in the treatment of patients undergoing hematopoietic stem cell trasplantation, who have developed a refractory graft versus host disease to first line of treatment. this is a prospective, multicenter, open to patients undergoing allogeneic transplantation in spanish hospitals, with one cohort of patients who receive four sequential doses of msc.

Eligibility criteria:
inclusion criteria: 1. diagnosis of ≥ grade ii graft versus host disease refractory to first-line treatment. 2. having been subjected to hematopoietic stem cell transplantation as treatment for malignant blood disorder has been controlled by the transplantation. the source may have been bone marrow cells or peripheral blood (pb) and coming from a family member or unrelated donor. 3. having been transplanted with myeloablative or non-myeloablative conditioning. 4. normal cardiac function (ef ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process 5. lung function without evidence of severe obstructive or restrictive lung disease. 6. age between 18 and 65 years. 7. women of childbearing age considered until one year after the last menstrual period and which have not undergone a surgical sterilization must obtain a negative pregnancy test at the time of inclusion in the study and commit to use a medically approved birth control while on study. 8. normal cardiac function (ef ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process. 9. signature of informed consent - exclusion criteria: 1. uncontrolled blood disorder by transplantation or progression at the time of inclusion. 2. bacterial, viral, fungal or is not being controlled. 3. any circumstance that the proposed trial dissuade medical treatment. pregnancy, lactation or refusal to use safe contraceptive measures. 4. patients who are currently participating or have completed their participation in a clinical trial in less than 3 months or who have participated in a clinical trial of advanced therapies at any previous time period. 5. patients who are currently participating or have completed their participation in a clinical trial in a period shorter than 3 months or who have participated in a clinical trial of advanced therapies at any previous time. 6. positive serology for hepatitis b , hepatitis c and aids virus. -
non-invasive oral biofilm characterization

Conditions: Gingivitis

Summary: there is a need for toothpastes that more effectively remove oral plaque and prevent re-formation. the objective of this study is to map the development and resolution of clinical gingivitis using conventional clinical examination and imaging data to determine how useful imaging techniques can be for evaluating how well a toothpaste cleans the teeth

the researcher can use imaging techniques to map changes in gingival blood flow during the development and resolution of fully reversible, early clinical gingivitis using standard-of-care clinical indices as gold standard the researcher can use imaging techniques to map inflammatory microstructural changes in the oral mucosa including swelling, vasodilation and edema during the development and resolution of fully reversible, early clinical gingivitis using standard-of-care clinical indices as gold standard

Eligibility criteria:
inclusion criteria: * adult male or female 18-25 years of age * volunteers with gingivitis but no periodontitis exclusion criteria: * subjects who must receive dental treatment during the study dates. * history of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses. allergy to personal care/consumer products or their ingredients. * individuals who have taken antibiotics in the previous 3 months * individuals who are pregnant or nursing

Keywords: gingivitis
ppar, rxr, and vdr expressions in peri-implantitis

Conditions: Periodontitis; Periimplantitis

Summary: abstract objective: periodontitis and peri-implantitis are the irreversible destructive diseases of the periodontal and peri-implant tissues. the present study aimed to determine the receptor expressions of peroxisome proliferative-activated receptor (ppar)-γ, retinoid x receptor (rxr)-α, and vitamin d receptor (vdr) in the diseased tissues around teeth and dental implants. methods: the study consisted of three groups as group 1; healthy controls (c, n=15), group 2; periodontitis patients with stage 3 grade b (p, n=15), and group 3; peri-implantitis patients (pi, n=15). periodontal clinical parameters as the plaque index (pi), gingival index (gi) and clinical attachment levels (cal) were recorded. gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing. hematoxylin-eosin (h\&e) and immunohistochemistry staining were performed. total inflammatory cell counts and fibroblast cell density were evaluated on h\&e-stained slides while ppar-γ, rxr-α, and vdr were evaluated via immunohistochemistry.


Eligibility criteria:
inclusion criteria: * healthy individuals * periodontitis patients * periimplantitis patients exclusion criteria: * smokers, * systemically compromised patients

Keywords: periodontitis periimplantitis rxr vdr
b-catenin in cutaneous squamous cell carcinoma and its mimickers

Conditions: Cutaneous Squamous Cell Carcinoma

Summary: examine the role of b-catenin in differentiation of cutaneous squamous cell carcinoma from other lesions that may be similar to it

skin cancer is one of the most common form of cancer worldwide. cutaneous squamous cell carcinoma is one of most common skin tumers that caused by many factors as ultra violet ,ionizing radiation and others . it was an advanced spectrum ranging from actinic keratosis to invasive and metastatic squmous cell carcinoma. correct identification of cutaneous squamous cell carcinoma is a challenge as it has both clinically and histopathologically mimickers. so the aim of this study is to identify the expression of b-catenin in cutaneous squamous cell carcinoma and its mimickers.

Eligibility criteria:
inclusion criteria: * tissue blocks with sufficient materials cases with sufficient data exclusion criteria: * tissue blocks with insufficient and necrotic materials. casas with insufficient data

Keywords: b-catenin cutaneous squamous cell carcinoma immunohistochemistry
safety and performance assessment of the decongestant seawater spray pocket valve enriched with essential oils in patients with acute rhinitis associated with nasal obstruction

Conditions: Acute Rhinitis; Nasal Obstruction; Rhinosinusitis; Rhinopharyngitis; Allergic Rhinitis

Summary: the purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by gilbert laboratories. the study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.


Eligibility criteria:
inclusion criteria: * 1. patient ≥ 12 years. * 2. patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis. * 3. a. informed adult patient who has given written consent prior to any study specific procedure. b. informed minor patient who has given assent and whose legal guardians have given written consent prior to any study-specific procedure. * 4. patient able to meet the study requirements for monitoring, spray use, and questionnaire completion. * 5. patient affiliated to a social security scheme. exclusion criteria: * 1. pregnant and/or breastfeeding woman * 2. hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray. * 3. diseases causing narrowing of the airways (e.g. asthma, chronic obstructive pulmonary disease (copd)) and/or respiratory insufficiency. * 4. patients with chronic nasal obstruction. * 5. patients on local and systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory drugs (nsaids), antibiotics and local antiseptics. * 6. concomitant use of other nasal sprays, essential oils for local nasal use, nasal creams or gels. * 7. patients under guardianship, curatorship or safeguard of justice.
the young women's breast cancer study

Conditions: Breast Cancer

Summary: the investigators are conducting a longitudinal cohort study of young women with breast cancer. the investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. after women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). the study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer.

this is a longitudinal cohort study of young women with breast cancer. over a 6-year period, the investigators aim to identify over 1,600 women age 40 and younger with newly diagnosed breast cancer from academic and community health care institutions. it is anticipated that 1,300 of these women will agree to participate in an observational study. patient surveys, medical record review, and blood and tissue collection will be utilized. women will be surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of 10 year following diagnosis). the study will investigate short and long-term disease and treatment issues, and psychosocial concerns at baseline and in follow-up among a cohort of young women (age 40 or younger) newly diagnosed with breast cancer. the investigators aim to characterize the population of young women at diagnosis and in follow-up regarding disease and psychosocial outcomes (e.g., presentation and disease characteristics, treatment patterns and quality of care, short and long-term side effects, and psychosocial concerns including fertility, sexual functioning, and menopausal issues). the investigators will also collect tumor and blood specimens to characterize the tumors, and bank for future studies including molecular evaluations of disease characteristics, genetic variability and hormonal levels in blood. ultimately, the investigators aim to develop predictors of outcome, and identify areas that may be amenable to intervention.

Eligibility criteria:
inclusion criteria: * female * diagnosis of breast cancer * age 40 or younger at diagnosis * informed consent obtained from patient * ability to understand written and spoken english to the extent necessary to complete the questionnaires exclusion criteria: * inability to understand written and spoken english to the extent necessary to complete the questionnaires * absence of informed consent

Keywords: breast cancer cohort young women survivorship fertility
cross-cultural use of performance-based functional assessment in alzheimer's disease

Conditions: Mild Cognitive Impairment; Healthy Controls

Summary: this study plans to assess the effectiveness of performance-based functional assessments (pbfas) and cognitive assessments in diagnosing alzheimer's disease in hispanic/latino populations. the information from this study will be analyzed with data from the rocky mountain alzheimer's disease center bio-ad study (nct02612376).


Eligibility criteria:
inclusion criteria: * persons with age-related mci or ad according to clinical diagnosis, consistent with national institute on aging-alzheimer's association (nia-aa) diagnostic criteria * community-dwelling controls * age \> 55 years * have been enrolled and completed at least one visit in the bio-ad study and consent to access their data (the rocky mountain alzheimer's disease center bio-ad study (clinicaltrials.gov identifier: nct02612376)) * have capacity to provide consent; capacity will be assessed at the time of consent * ability to complete baseline assessments * has informant (study partner) available to complete functional interviews/survey measures exclusion criteria: * presence of concomitant medical, neurological, or psychiatric illness or condition that in the opinion of the investigators would confound interpretation of study results. these include: * korsakoff encephalopathy; * active substance abuse; * hepatitis c; * opportunistic brain infection; * brain tumor; * active neoplastic disease (skin tumors other than melanoma are not exclusionary; participants with stable prostate cancer may be included at the discretion of the project director); * multiple sclerosis; * history of clinically significant stroke; * current evidence or history in the past 2 years of * focal brain lesion, * head injury with loss of consciousness in the past year, or * dsm-5 criteria for any major psychiatric disorder, including 1. psychosis, 2. uncontrolled major depression, 3. bipolar disorder, 4. alcohol or substance abuse; 5. blindness, 6. deafness or 7. any other disability which may prevent the participant from participating or cooperating in the protocol. * prisoners * any contraindication for mri
18fdg-pet imaging to detect changes in airways inflammation in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to determine if 18fluorodeoxyglucose (fdg) positron emission tomography (pet) imaging can detect changes in airways inflammation in cystic fibrosis (cf) patients after treatment for a pulmonary exacerbation.

neutrophils play a key role in the pathogenesis of cf lung disease. we know that neutrophilic inflammation is related to a decline in pulmonary function. therefore, early anti-inflammatory intervention is an opportunity to slow this irreversible pulmonary destruction. however, the development of sensitive, non-invasive diagnostic tools of airways inflammation is essential to the study and implementation of anti-inflammatory therapies. our current armentarium of measures of airways inflammation is limited. bal is invasive and not clinically acceptable as a tool for the serial measurement of inflammation. sputum samples are highly variable and not reliable. 18fdg-pet is a promising tool because it is non invasive, has been shown to quantify the amount and location of neutrophilic inflammation and has the potential to be used to track inflammation over time. therefore, the goal of this research study is to evaluate the ability of 18fdg -pet imaging to detect changes in airways inflammation in cf patients in response to conventional treatment for a pulmonary exacerbation

Eligibility criteria:
inclusion criteria: * diagnosis of cf as defined by two or more clinical features of cf and a documented sweat chloride \> 60meq/l by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations * informed consent and verbal assent (as appropriate) provided by the subject's parent or legal guardian and the subject * ages 6-18 and able to perform reproducible spirometry * admission to the hospital for sick children for a pulmonary exacerbation exclusion criteria: * inability to perform reproducible spirometry * diagnosis of cystic fibrosis related diabetes (cfrd) * medical instability that would preclude the ability to perform pet imaging * fev1% predicted \< 40% * the use of supplementary oxygen * pregnancy or breastfeeding * severe claustrophobia

Keywords: 18fdg-pet imaging airway inflammation cystic fibrosis pediatric pulmonary exacerbation
the must-pc: a pilot study to assess symptom burden of co-occuring symptoms

Conditions: Palliative Care

Summary: in this pilot study, physicians and nurse practitioners working in different care settings will use must-pc, for adult patients with any life-limiting iilness, for whom the surprise question is answered negatively: if the hcp answers "no" to the question "would i be surprised if this patiënt died in the next 12 months?''. in total, at least 20 eligible patients will be recruited and asked to perform all study assessments.

in this pilot study, physicians and nurse practitioners working in different care settings will use must-pc, for adult patients with any life-limiting iilness, for whom the surprise question is answered negatively: if the hcp answers "no" to the question "would i be surprised if this patiënt died in the next 12 months?''. in total, at least 20 eligible patients will be recruited and asked to perform all study assessments. after a baseline screening assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score £4 on the 11 point scale on the utrecht symptom diary, will be asked to fiil out the utrecht symptom diary during two weeks. in the first week twice daily (morning and evening), in the second week once daily (evening).

Eligibility criteria:
inclusion criteria: * patients identified as in a palliative care trajectory (based on a negative answer to the surprise question "would i be surprised if this patiënt died in the next 12 months?") * all primary diseases (cancer, non-cancer (e.g. copd, haart failure, frailty) * patients should have at least two symptoms on the utrecht symptom diary with a numeric rating score of 4 or higher * life expectancy of at least 4 weeks * able to fill out dutch questionnaires * informed consent exclusion criteria: * patients who are unable or unwilling to self-assess their symptoms at baseline.